This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416.
Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.
Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822.
Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT . Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477–484.
Thornton PD, Gruszka-Westwood AM, Hamoudi RA, Atkinson S, Kaczmarek P, Morilla RM et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004; 5: 47–54.
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963–3967.
Smardova J, Pavlova S, Koukalova H . Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002; 8: 245–251.
Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996; 12: 813–818.
Acknowledgements
This work was supported by Grants NR8445-3, NR/8068-3, NR8443-3 and NR8448-3 provided by the Internal Grant Agency of the Ministry of Health of the Czech Republic, by the Research Proposal 0021622415 from the Ministry of Education of the Czech Republic and by the European Research Initiative on CLL (ERIC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trbusek, M., Malcikova, J., Smardova, J. et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 20, 1159–1161 (2006). https://doi.org/10.1038/sj.leu.2404195
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404195
This article is cited by
-
Detection and clinical significance of genes in primary gastrointestinal MALT lymphoma
Tumor Biology (2014)
-
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
Leukemia (2010)
-
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
Leukemia (2009)
-
How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance
Leukemia (2008)
-
Spectrum of p53 mutations in low-grade B-cell malignancies
Leukemia (2008)